Blog
RSS FeedPosted by Michael Wonder on 15 Nov 2022
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred ...
Posted by Michael Wonder on 15 Nov 2022
ATAGI update on boosters following COVID-19 meeting on 11 November 2022
15 November 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 11 November ...
Posted by Michael Wonder on 15 Nov 2022
COVID-19 vaccine safety report (3 November 2022)
3 November 2022 - To 30 October 2022, the TGA has received 704 reports which have been assessed as likely to ...
Posted by Michael Wonder on 08 Nov 2022
New COVID-19 variant leads to increase in cases
8 November 2022 - A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, on the increase in COVID-19 cases ...
Posted by Michael Wonder on 28 Oct 2022
TGA provisionally approves Pfizer bivalent COVID-19 vaccine for use as a booster dose in adults
28 October 2022 - On 27 October 2022, the TGA provisionally approved Pfizer’s bivalent COVID-19 vaccine, tozinameran and riltozinameran (COMIRNATY Original/Omicron ...
Posted by Michael Wonder on 24 Oct 2022
ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
24 October 2022 - Recommendations from the Australian Technical Advisory Group on Immunisation on Pfizer booster doses for children aged 5 ...
Posted by Michael Wonder on 20 Oct 2022
COVID-19 vaccine safety report (20 October 2022)
20 October 2022 - To 16 October 2022, the TGA has received 705 reports which have been assessed as likely to ...
Posted by Michael Wonder on 20 Oct 2022
TGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and older
20 October 2022 - On 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, Spikevax (elasomeran), for use as ...
Posted by Michael Wonder on 17 Oct 2022
Calls for TGA to withdraw Covid drug approval
17 October 2022 - The medicines regulator is facing calls to withdraw its provisional approval for the antiviral drug molnupiravir ...
Posted by Michael Wonder on 07 Oct 2022
COVID-19 vaccine safety report (6 October 2022)
6 October 2022 - To 2 October 2022, the TGA has received 703 reports which have been assessed as likely to ...
Posted by Michael Wonder on 30 Sep 2022
TGA grants provisional determination to Moderna’s COVID-19 bivalent (Original plus Omicron BA.4/BA.5) booster dose vaccine
30 September 2022 - On 28 September 2022, the TGA granted a provisional determination to Moderna's bivalent COVID-19 vaccine candidate: elasomeran ...
Posted by Michael Wonder on 29 Sep 2022
TGA provisionally approves Pfizer’s COVID-19 vaccine, Comirnaty (tozinameran) for use in children aged 6 months to less than 5 years
29 September 2022 - On 29 September 2022, the TGA provisionally approved a paediatric dose of Pfizer’s COVID-19 vaccine, Comirnaty (tozinameran), ...
Posted by Michael Wonder on 27 Sep 2022
COVID-19 vaccine procurement review says rapid access to vaccines and treatments key to on-going protection of Australians
27 September 2022 - Medicines Australia welcomes the independent review of Australia’s COVID-19 vaccine and treatment procurements by Professor Jane ...
Posted by Michael Wonder on 27 Sep 2022
Halton review into vaccine and treatment procurement
27 September 2022 - Professor Jane Halton AO has handed to Government her independent review of Australia’s COVID-19 vaccine and treatment ...
Posted by Michael Wonder on 26 Sep 2022
Novavax appeals to ATAGI to change advice as vaccine uptake falls behind
25 September 2022 - Novavax was hailed as the fix to Australia’s low inoculation rate and “the vaccine for anti-vaxxers”. So ...